Heart, Men's Health, Age related illnesses, Women's Health | June 23, 2014 | Author: The Super Pharmacist
Ischaemic heart disease is a leading form of heart failure. It is also known by other names, including coronary myopathy or coronary artery disease. It refers to the reduction of blood flow into cardiac tissue (i.e. the heart), mainly associated with the accumulation of cholesterol plaques (atherosclerosis) on the interior walls of coronary arteries (the vessels that pump blood into the heart muscle itself).
Over time, this may result in a significant decrease in the concentration of oxygen and other molecules to cardiac muscle tissue, without which these tissues cannot function properly. This may culminate in the death of heart tissue due to starvation of nutrients and energy.
Therefore, ischaemic heart disease may have severe consequences for the overall health of patients affected. This condition is thought to be a leading cause of death worldwide. Recent estimates indicate that this condition is responsible for up to 46% of all deaths caused by cardiovascular disease (CVD) in men, and up to 38% of these deaths in women. CVD is associated with approximately 30% of all preventable death worldwide.
Ischaemic heart disease is associated with many risk factors. The most prevalent include:
Genetic factors may also contribute to the risk of ischaemic heart disease; for example, the condition is associated with individuals who tend to produce high levels of certain blood proteins and other molecules. These include fibrinogen and C-reactive protein.
Lifestyle factors. Ischaemic heart disease may be linked to certain lifestyle factors, such as smoking, reduced daily exercise and a regular intake of certain fats.
Health conditions. It is also indirectly linked with certain conditions (e.g. obesity) that are also associated with major risk factors.
There are also cases of this condition to which none of these factors apply, and/or in which atherosclerosis is not detected. This is known as idiopathic heart disease, or cardiac syndrome X11.
The symptoms of ischaemic heart disease are often chronic, and are also acute indications of a heart attack, or large-scale failure of cardiac muscle. These include angina pectoris, or discomfort and pain in the chest area. Angina pectoris may indicate 'stable' ischaemic heart disease, i.e. cases where arterial narrowing is present, but without immediate danger of heart attack, and the condition is manageable with treatment (see below).
More sudden-onset chest pains are also a sign of a heart attack, or the death of cardiac tissue. An acute and life-threatening dysfunction of cardiac muscle is often termed a heart attack or acute myocardial infarction. This is often accompanied by significant difficulty in breathing, fatigue, sweating and nausea.
Diagnosis of ischaemic heart disease may be achieved by one or more direct imaging techniques, such as magnetic resonance imaging (MRI), angiography, near-infrared spectroscopy, intravascular ultrasound or echocardiography.
It may also be detected by comparing an electrocardiogram (ECG) (non-invasive readings of heart activity translated to a graph) while the patient undergoes experimental stress (such as exercise) with a baseline or resting ECG.
Ischaemic heart disease detection under emergency circumstances (i.e. heart attack) may include emergency angiography or surgical interventions to visualise or treat the myocardial failure.
Ischaemic heart disease may also persist without noticeable symptoms ('silent ischaemic heart disease') which may culminate in an unexpected acute event such as a heart attack.
Treatments for ischaemic heart disease may be administered in response to the diagnosis of the condition (i.e. to an individual with a 'stable' form of the disease), in the course of acute heart failure or after an acute incident. These treatments are mainly pharmaceutical in nature.
Organic nitrates are a class of drugs that act through their relaxing effect on smooth muscle, which is found in arteries. The rationale is that this will contribute to increased arterial dilation ('vasodilation'), and thus reduce blood flow constriction in arteries affected by stenosis or atherosclerosis. Organic nitrates include:
These drugs may treat stable ischaemic heart disease and hypertension. They may also be administered following an acute attack in combination with some other vasodilators; hydralazine and ISDN are a particularly effective example of this. Organic nitrates act by breaking down into nitric oxide (NO) in the body, which stimulates the relaxation of smooth muscle. It was thought that the closely-related molecule nitroglycerine works in the same matter. However, recent research indicates that this classic heart disease treatment may activate the enzyme nitric oxide synthase (which converts other compounds to NO) instead. Beta-blockers are another popular treatment for ischaemic heart disease. These inhibit the action of the neurotransmitters noradrenaline and adrenaline, which mainly act to increase cardiac muscle movement and oxygen use. Therefore, these drugs reduce the demand for oxygen and other molecules, and may contribute in this way to moderate muscle cell death due to nutrient starvation. Beta-blockers include:
The latter is counterindicated if nitrates are also administered, as this may cause excessive hypotension36. These drops in blood pressure are in themselves a potentially harmful condition. Other drugs used to treat ischaemic heart disease act to reduce cholesterol formation in the body, so as to prevent plaque formation within coronary arteries. The most prevalent of these would be the statins. This class of drugs inhibit the first step of the conversion of dietary fats (triglycerides) to cholesterol. Fibrates reduce the concentration of triglycerides in the blood, while ezetimibe reduces dietary cholesterol absorption from the intestines.
Treatments for this condition also include surgery, as mentioned above. These invasive interventions include:
Coronary artery bypass graft (also popularly known simply as a 'bypass'), in which a length of another artery is autografted (i.e. taken from the patient in question) onto the coronary vascular system to take over the functions of a blocked artery.
Angioplasty, in which coronary arteries are opened or unblocked. This may be achieved through the implantation of a stent. This is a hollow tube which is placed in an affected artery in order to keep it open.
These interventions may be a part of emergency treatment, or carried out to prevent an acute cardiac event.
The role of behaviour or lifestyle modifications in preventing or treating ischaemic heart disease has also been recognised in the last few years.
These can include:
In conclusion, ischaemic heart disease is a common cause of preventable death, the risk of which may be ameliorated by maintaining a healthy lifestyle and diet. Treatment for this condition is well-researched and developed.
Mendis S, Puska P, Norrving B, World Health Organization., World Heart Federation., World Stroke Organization. Global atlas on cardiovascular disease prevention and control. Geneva: World Health Organization in collaboration with the World Heart Federation and the World Stroke Organization; 2011.
Finsterer J, Stollberger C, Bonner E. Acquired noncompaction associated with coronary heart disease and myopathy. Heart & lung : the journal of critical care.2010;39(3):240-241.
Ungprasert P, Suksaranjit P, Spanuchart I, Leeaphorn N, Permpalung N. Risk of coronary artery disease in patients with idiopathic inflammatory myopathies: A systematic review and meta-analysis of observational studies. Seminars in arthritis and rheumatism.2014.
Mostowik M, Palka I, Gajos G, Nessler J, Gackowski A. Mitral and aortic calcifications and cerebrovascular ischemic episodes in patients with coronary artery disease. Polskie Archiwum Medycyny Wewnetrznej.2014.
Parmley WW. Pathophysiology of congestive heart failure. The American journal of cardiology.1985;56(2):7a-11a.
Vanuzzo D, Pilotto L, Mirolo R, Pirelli S. [Cardiovascular risk and cardiometabolic risk: an epidemiological evaluation]. Giornale italiano di cardiologia (2006).2008;9(4 Suppl 1):6s-17s.
Whayne TF, Jr. Atherosclerosis: current status of prevention and treatment. The International journal of angiology : official publication of the International College of Angiology, Inc.2011;20(4):213-222.
Kosuge M, Kimura K, Ishikawa T, et al. Differences between men and women in terms of clinical features of ST-segment elevation acute myocardial infarction. Circulation journal : official journal of the Japanese Circulation Society.2006;70(3):222-226.
Roberts R. Genetics of Coronary Artery Disease: An Update. Methodist DeBakey cardiovascular journal.2014;10(1):7-12.
Krintus M, Kozinski M, Kubica J, Sypniewska G. Critical appraisal of inflammatory markers in cardiovascular risk stratification. Critical reviews in clinical laboratory sciences.2014:1-17.
Andishmand A, Ansari Z, Soltani M, Mirshamsi H, Raafat S. Vitamin D replacement therapy in patients with cardiac syndrome X. Perfusion.2014.
Di Monaco A, Sestito A. The patient with chronic ischemic heart disease. Role of ranolazine in the management of stable angina. European review for medical and pharmacological sciences.2012;16(12):1611-1636.
Zhao W, Zhang F, Li Z, Yu H, Li Z, Gao W. Soluble CD40 ligand is associated with angiographic severity of coronary artery disease in patients with acute coronary syndrome. Chinese medical journal.2014;127(12):2218-2221.
Momiyama Y. Association between plasma apelin levels and coronary collateral development in patients with stable angina pectoris. Atherosclerosis.2014;235(2):349-350.
Grzywocz P, Mizia-Stec K, Wybraniec M, Chudek J. Adipokines and endothelial dysfunction in acute myocardial infarction and the risk of recurrent cardiovascular events. Journal of cardiovascular medicine (Hagerstown, Md.).2014.
Fennessy MM, Fink AM, Eckhardt AL, et al. Gender differences in fatigue associated with acute myocardial infarction. Journal of cardiopulmonary rehabilitation and prevention.2010;30(4):224-230.
Berg J, Bjorck L, Dudas K, Lappas G, Rosengren A. Symptoms of a first acute myocardial infarction in women and men. Gender medicine.2009;6(3):454-462.
Manka R, Paetsch I, Kozerke S, et al. Whole-heart dynamic three-dimensional magnetic resonance perfusion imaging for the detection of coronary artery disease defined by fractional flow reserve: determination of volumetric myocardial ischaemic burden and coronary lesion location. European heart journal.2012;33(16):2016-2024.
Jimenez-Juan L, Nguyen ET, Wintersperger BJ, et al. Failed heart rate control with oral metoprolol prior to coronary CT angiography: effect of additional intravenous metoprolol on heart rate, image quality and radiation dose. The international journal of cardiovascular imaging.2013;29(1):199-206.
Brugaletta S, Sabate M. Assessment of Plaque Composition by Intravascular Ultrasound and Near-Infrared Spectroscopy. Circulation journal : official journal of the Japanese Circulation Society.2014.
Mantovani F, Abdelmoneim SS, Zysek V, Eifert-Rain S, Mulvagh SL. Effect of Stress Echocardiography Testing on Changes in Cardiovascular Risk Behaviors in Postmenopausal Women: A Prospective Survey Study. Journal of women's health (2002).2014.
Alqarawi WA, Goodman SG, Yan RT, et al. Prognostic implications of prominent R wave in electrocardiographic leads v1 or v2 in patients with acute coronary syndrome. The American journal of cardiology.2014;113(12):1962-1967.
Schlett CL, Jr JW, Schoepf UJ, et al. Differences in coronary artery disease by CT angiography between patients developing unstable angina pectoris vs. major adverse cardiac events. European journal of radiology.2014;83(7):1113-1119.
Joffre J, Varenne O, Bougouin W, Rosencher J, Mira JP, Cariou A. Stent thrombosis: An increased adverse event after angioplasty following resuscitated cardiac arrest. Resuscitation.2014;85(6):769-773.
Zhang L, Li H, Zhang S, Jaacks LM, Li Y, Ji L. Silent myocardial ischemia detected by single photon emission computed tomography (SPECT) and risk of cardiac events among asymptomatic patients with type 2 diabetes: a meta-analysis of prospective studies. Journal of diabetes and its complications.2014;28(3):413-418.
Herrmann J, Gersh BJ, Goldfinger JZ, et al. Body Mass Index and Acute and Long-Term Outcomes After Acute Myocardial Infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial). The American journal of cardiology.2014;114(1):9-16.
Chhabra L, Spodick DH. Role of epicardial fat in atrial fibrillation after coronary artery bypass surgery. The American journal of cardiology.2014;113(12):2090.
Nossaman VE, Nossaman BD, Kadowitz PJ. Nitrates and nitrites in the treatment of ischemic cardiac disease. Cardiology in review.2010;18(4):190-197.
Golwala HB, Thadani U, Liang L, et al. Use of hydralazine-isosorbide dinitrate combination in African American and other race/ethnic group patients with heart failure and reduced left ventricular ejection fraction. Journal of the American Heart Association.2013;2(4):e000214.
Lai J, Wu B, Sun J, Shang Y, Zhu J. Long-term isosorbide mononitrate treatment impairs endothelial function in patients with coronary artery disease. Coronary artery disease.2013;24(7):566-571.
Lim WY, Woldman S. Pharmacological management of chronic heart failure: old drugs, new drugs and new indications. British journal of hospital medicine (London, England : 2005).2013;74(2):C18-22.
Bonini MG, Stadler K, Silva SO, et al. Constitutive nitric oxide synthase activation is a significant route for nitroglycerin-mediated vasodilation. Proceedings of the National Academy of Sciences of the United States of America.2008;105(25):8569-8574.
Bangalore S, Makani H, Radford M, et al. Clinical Outcomes with beta-blockers for Myocardial Infarction A Meta-Analysis of Randomized Trials. The American journal of medicine.2014.
Hardwick JC, Southerland EM, Girasole AE, Ryan SE, Negrotto S, Ardell JL. Remodeling of intrinsic cardiac neurons: effects of beta-adrenergic receptor blockade in guinea pig models of chronic heart disease. American journal of physiology. Regulatory, integrative and comparative physiology.2012;303(9):R950-958.
Ceschan NE, Bucala V, Ramirez-Rigo MV. New alginic acid-atenolol microparticles for inhalatory drug targeting. Materials science & engineering. C, Materials for biological applications.2014;41:255-266.
Premaratna R, Sathishchandra H, Thilakaratna Y, Shantharaj W, de Silva H. Effects of propranolol and nitrates on exercise capacity, respiratory minute volume and capillary oxygen saturation during exercise in cirrhotic patients with portal hypertension. Hepatology research : the official journal of the Japan Society of Hepatology.2002;24(2):152.
Forcadell-Peris MJ, de Diego-Cabanes C. [Rhabdomyolysis secondary to simvastatin and phenofibrate.]. Semergen / Sociedad Espanola de Medicina Rural y Generalista.2014.
Tribble DL, Farnier M, Macdonell G, et al. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia. Metabolism: clinical and experimental.2008;57(6):796-801.
Huxley RR, Woodward M. Cigarette smoking as a risk factor for coronary heart disease in women compared with men: a systematic review and meta-analysis of prospective cohort studies. Lancet.2011;378(9799):1297-1305.
Oliveira NL, Ribeiro F, Alves AJ, Campos L, Oliveira J. The effects of exercise training on arterial stiffness in coronary artery disease patients: a state-of-the-art review. Clinical physiology and functional imaging.2014;34(4):254-262.
Hord NG. Dietary nitrates, nitrites, and cardiovascular disease. Current atherosclerosis reports.2011;13(6):484-492.
Heran BS, Chen JM, Ebrahim S, et al. Exercise-based cardiac rehabilitation for coronary heart disease. The Cochrane database of systematic reviews.2011(7):Cd001800.